Froestl Wolfgang, Muhs Andreas, Pfeifer Andrea
AC Immune SA, EPFL, Lausanne, Switzerland.
J Alzheimers Dis. 2014;41(4):961-1019. doi: 10.3233/JAD-140228.
Scientists working in the fields of Alzheimer's disease and, in particular, cognitive enhancers are very productive. The review "Cognitive enhancers (nootropics): drugs interacting with receptors" was accepted for publication in July 2012. Since then, new targets for the potential treatment of Alzheimer's disease were identified. This update describes drugs interacting with 42 receptors versus 32 receptors in the first paper. Some compounds progressed in their development, while many others were discontinued. The present review covers the evolution of research in this field through March 2014.
从事阿尔茨海默病领域研究，尤其是认知增强剂研究的科学家们成果丰硕。综述《认知增强剂（促智药）：与受体相互作用的药物》于2012年7月被接受发表。自那时起，确定了阿尔茨海默病潜在治疗的新靶点。本次更新描述了与第一篇论文中32种受体相比，与42种受体相互作用的药物。一些化合物在其研发中取得进展，而许多其他化合物则被停止研发。本综述涵盖了截至2014年3月该领域研究的进展情况。
